Pub Date : 2025-12-01DOI: 10.1016/j.psycr.2025.100275
Ezie Nguyen , Allison Watkins , Lauren Wells
{"title":"Retraction notice to “Pseudocyesis in a deployed military member” [Psychiatry Research Case Reports Volume 2, Issue 2, December 2023, 100183]","authors":"Ezie Nguyen , Allison Watkins , Lauren Wells","doi":"10.1016/j.psycr.2025.100275","DOIUrl":"10.1016/j.psycr.2025.100275","url":null,"abstract":"","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100275"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145683667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.psycr.2025.100277
TammieLee Demler , TammieLee Demler , Samara White
{"title":"Retraction notice to “Exploring the Risk of Magnesium Use for Antipsychotic Induced Constipation: A Case study for consideration” [Psychiatry Research Case Reports Volume 2, Issue 1, June 2023, 100132]","authors":"TammieLee Demler , TammieLee Demler , Samara White","doi":"10.1016/j.psycr.2025.100277","DOIUrl":"10.1016/j.psycr.2025.100277","url":null,"abstract":"","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100277"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145683656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.psycr.2025.100272
Ila Gautham , Annise Wilson
{"title":"Retraction notice to “Diagnosis of unsuspected catatonia with an inadvertent lorazepam challenge test” [Volume 1, Issue 2, December 2022, 100073]","authors":"Ila Gautham , Annise Wilson","doi":"10.1016/j.psycr.2025.100272","DOIUrl":"10.1016/j.psycr.2025.100272","url":null,"abstract":"","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100272"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145683661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.psycr.2025.100278
John F. Gunn III , David Lester
{"title":"Removal notice to “Announcing Suicide on the Internet: A Case Report” [Psychiatry Research Case Reports Volume 1, Issue 1, June 2022, 100010]","authors":"John F. Gunn III , David Lester","doi":"10.1016/j.psycr.2025.100278","DOIUrl":"10.1016/j.psycr.2025.100278","url":null,"abstract":"","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100278"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145683657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.psycr.2025.100264
Jill M Williams , Mary Barna Bridgeman , Lisa Laitman
This article has been retracted: please see Elsevier policy on article withdrawal (https://www.elsevier.com/about/policies-and-standards/article-withdrawal).
A post-publication investigation conducted by Elsevier's Research Integrity & Publishing Ethics team on behalf of the journal determined that the patient or nominated representative of the patient did not provide informed consent for this publication in line with the journal's policy. The editor has decided to retract the article.
{"title":"Retraction notice to “A vulnerable young adult using cannabis for therapeutic purposes despite emerging psychosis” [Psychiatry Research Case Reports 1 (2022) 100037]","authors":"Jill M Williams , Mary Barna Bridgeman , Lisa Laitman","doi":"10.1016/j.psycr.2025.100264","DOIUrl":"10.1016/j.psycr.2025.100264","url":null,"abstract":"<div><div>This article has been retracted: please see Elsevier policy on article withdrawal (<span><span>https://www.elsevier.com/about/policies-and-standards/article-withdrawal</span><svg><path></path></svg></span>).</div><div>A post-publication investigation conducted by Elsevier's Research Integrity & Publishing Ethics team on behalf of the journal determined that the patient or nominated representative of the patient did not provide informed consent for this publication in line with the journal's policy. The editor has decided to retract the article.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100264"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145683659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-13DOI: 10.1016/j.psycr.2025.100299
Daniel Morgan , Gurvir Singh Rai , Danilo Arnone
There is a paucity of literature regarding clozapine initiation in patients with haematologic malignancies. We present the case of a patient with chronic lymphocytic leukaemia (CLL) and schizoaffective disorder whose clozapine was discontinued and restarted. A woman in her 60s presented to the emergency department with hypotension and symptomatic pancytopenia. Clozapine was discontinued due to the risk of neutropenia during her admission to the haematology service. Bone marrow aspiration revealed that the pancytopenia was due to CLL clonal invasion, and the decision was made to restart clozapine. The subsequent development of hospital-acquired pneumonia led to clozapine discontinuation. An evaluation of the harms and benefits of clozapine re-initiation is discussed considering the possible additive effects of clozapine and CLL on degrading immune function, the risk of opportunistic infections, and the cytotoxic effects of CLL treatment. In medicated patients with stable psychopathology the introduction of clozapine after completion of CCL treatment can help minimise the risk of physical complications. Earlier introduction of clozapine may be justified in symptomatic patients with close monitoring. Informed decisions should be guided by patients’ preferences after judicious evaluation of risks and benefits. Haematology-psychiatry collaboration is essential to best manage cases with complex, comorbid psychiatric and haematological conditions.
{"title":"Clozapine treatment in chronic lymphocytic leukaemia and pancytopenia","authors":"Daniel Morgan , Gurvir Singh Rai , Danilo Arnone","doi":"10.1016/j.psycr.2025.100299","DOIUrl":"10.1016/j.psycr.2025.100299","url":null,"abstract":"<div><div>There is a paucity of literature regarding clozapine initiation in patients with haematologic malignancies. We present the case of a patient with chronic lymphocytic leukaemia (CLL) and schizoaffective disorder whose clozapine was discontinued and restarted. A woman in her 60s presented to the emergency department with hypotension and symptomatic pancytopenia. Clozapine was discontinued due to the risk of neutropenia during her admission to the haematology service. Bone marrow aspiration revealed that the pancytopenia was due to CLL clonal invasion, and the decision was made to restart clozapine. The subsequent development of hospital-acquired pneumonia led to clozapine discontinuation. An evaluation of the harms and benefits of clozapine re-initiation is discussed considering the possible additive effects of clozapine and CLL on degrading immune function, the risk of opportunistic infections, and the cytotoxic effects of CLL treatment. In medicated patients with stable psychopathology the introduction of clozapine after completion of CCL treatment can help minimise the risk of physical complications. Earlier introduction of clozapine may be justified in symptomatic patients with close monitoring. Informed decisions should be guided by patients’ preferences after judicious evaluation of risks and benefits. Haematology-psychiatry collaboration is essential to best manage cases with complex, comorbid psychiatric and haematological conditions.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100299"},"PeriodicalIF":0.0,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Familial Cerebral Cavernous Malformations (FCCMs) are associated with symptomatic clinical findings, including neurological deficits and seizures, a positive family history, and supportive gene mutations. Current evidence on neuropsychiatric manifestations is limited to case reports, primarily describing mood and anxiety symptoms. The use of Electroconvulsive Therapy (ECT) has been limited, largely due to concerns about precipitating cavernoma bleeding. Notably, there are no documented cases of psychotic manifestations in cavernomas that are not actively haemorrhagic.
Methods and Results
We report on two siblings with FCCMs, diagnosed based on brain imaging and family history, who presented with rare neuropsychiatric symptoms of psychosis.
Case 1
A 15-year-old female presented with auditory hallucinations, delusions of erotomania and passivity, affective symptoms including overfamiliarity and disinhibition, and significant aggression toward herself and others. She demonstrated resistance to multiple trials of antipsychotics and lithium. Treatment with clozapine and ECT was required, alongside propranolol to manage blood pressure and mitigate the risk of cavernoma bleeding during ECT.
Case 2
A 21-year-old male presented with auditory hallucinations, delusions of guilt, and aggression. He also exhibited treatment resistance and required clozapine for symptom management.
Conclusions
Patients with FCCMs may exhibit genetic and clinical overlaps, posing significant medical challenges when managing psychotic symptoms. Their psychosis may demonstrate resistance to conventional treatments. ECT appears to be a novel, potentially safe, and effective therapeutic option when precautions are taken to minimize the risk of cavernoma bleeding.
{"title":"Treatment-resistant psychosis in familial cerebral cavernous malformation: A case series","authors":"Tianyi Hui , Thanita Pilunthanakul , Li Keat Oon , Charmaine Tang","doi":"10.1016/j.psycr.2025.100298","DOIUrl":"10.1016/j.psycr.2025.100298","url":null,"abstract":"<div><h3>Background</h3><div>Familial Cerebral Cavernous Malformations (FCCMs) are associated with symptomatic clinical findings, including neurological deficits and seizures, a positive family history, and supportive gene mutations. Current evidence on neuropsychiatric manifestations is limited to case reports, primarily describing mood and anxiety symptoms. The use of Electroconvulsive Therapy (ECT) has been limited, largely due to concerns about precipitating cavernoma bleeding. Notably, there are no documented cases of psychotic manifestations in cavernomas that are not actively haemorrhagic.</div></div><div><h3>Methods and Results</h3><div>We report on two siblings with FCCMs, diagnosed based on brain imaging and family history, who presented with rare neuropsychiatric symptoms of psychosis.</div></div><div><h3>Case 1</h3><div>A 15-year-old female presented with auditory hallucinations, delusions of erotomania and passivity, affective symptoms including overfamiliarity and disinhibition, and significant aggression toward herself and others. She demonstrated resistance to multiple trials of antipsychotics and lithium. Treatment with clozapine and ECT was required, alongside propranolol to manage blood pressure and mitigate the risk of cavernoma bleeding during ECT.</div></div><div><h3>Case 2</h3><div>A 21-year-old male presented with auditory hallucinations, delusions of guilt, and aggression. He also exhibited treatment resistance and required clozapine for symptom management.</div></div><div><h3>Conclusions</h3><div>Patients with FCCMs may exhibit genetic and clinical overlaps, posing significant medical challenges when managing psychotic symptoms. Their psychosis may demonstrate resistance to conventional treatments. ECT appears to be a novel, potentially safe, and effective therapeutic option when precautions are taken to minimize the risk of cavernoma bleeding.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100298"},"PeriodicalIF":0.0,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-23DOI: 10.1016/j.psycr.2025.100297
Hisanobu Kaiya , Takeshi Otowa
Freud described three types of anxiety attacks: pure anxiety attacks (PAA), characterized by sudden affective surges without ideation or somatic symptoms; anxious-depressive attacks (ADA), involving ruminative and depressive thoughts; and panic attacks (PA), dominated by autonomic arousal. Although PA has been extensively documented, PAA and ADA have received limited clinical attention.
In this retrospective case series, we reviewed outpatient clinic charts and descriptively classified recorded anxiety episodes by their predominant features, which enabled us to identify attacks lacking prominent physical symptoms. Two Japanese outpatients illustrate how these subtypes can manifest and shift within the same individual. Case A showed a temporal progression from PA to PAA and then ADA, each phase marked by distinct features. Case B initially presented ADA, followed by episodes of PA and PAA, sometimes alternating rapidly within a single episode.
These observations suggest a shared psychodynamic origin expressed through somatic, cognitive, or affective channels depending on individual and situational factors. Distinguishing PAA and ADA from PA is clinically significant, as these subtypes lack the somatic arousal that typically guides diagnosis and may show different responses to psychological versus pharmacological strategies. Our findings highlight less recognized non-somatic variants that might otherwise be overlooked in clinical practice and point toward more tailored therapeutic approaches.
{"title":"Pure, anxious-depressive, and panic anxiety attacks: A Freud-inspired case series","authors":"Hisanobu Kaiya , Takeshi Otowa","doi":"10.1016/j.psycr.2025.100297","DOIUrl":"10.1016/j.psycr.2025.100297","url":null,"abstract":"<div><div>Freud described three types of anxiety attacks: pure anxiety attacks (PAA), characterized by sudden affective surges without ideation or somatic symptoms; anxious-depressive attacks (ADA), involving ruminative and depressive thoughts; and panic attacks (PA), dominated by autonomic arousal. Although PA has been extensively documented, PAA and ADA have received limited clinical attention.</div><div>In this retrospective case series, we reviewed outpatient clinic charts and descriptively classified recorded anxiety episodes by their predominant features, which enabled us to identify attacks lacking prominent physical symptoms. Two Japanese outpatients illustrate how these subtypes can manifest and shift within the same individual. Case A showed a temporal progression from PA to PAA and then ADA, each phase marked by distinct features. Case B initially presented ADA, followed by episodes of PA and PAA, sometimes alternating rapidly within a single episode.</div><div>These observations suggest a shared psychodynamic origin expressed through somatic, cognitive, or affective channels depending on individual and situational factors. Distinguishing PAA and ADA from PA is clinically significant, as these subtypes lack the somatic arousal that typically guides diagnosis and may show different responses to psychological versus pharmacological strategies. Our findings highlight less recognized non-somatic variants that might otherwise be overlooked in clinical practice and point toward more tailored therapeutic approaches.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100297"},"PeriodicalIF":0.0,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145415596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.1016/j.psycr.2025.100295
Sara Briker , Aria Vitale , Sara Wierbowski , Jonathan Galla , Kelly Hamilton , Steven Potter , Jennifer F. Schreiber
The introduction of tacrolimus as an anti-rejection medication has markedly improved the outcomes of patients receiving organ transplants. While the use of tacrolimus has been instrumental in preventing organ rejection, especially in the case of pancreas and multi-organ transplants, the neuropsychiatric side effects are less commonly reported. Here, we present the complicated psychiatric and behavioral presentation of a 38-year-old woman with a psychiatric history of treatment-resistant depression, anxiety, and an unspecified eating disorder, who had been maintained uneventfully on tacrolimus after receiving a living-donor kidney transplant two years earlier. The patient then underwent an isolated pancreas transplant. Psychiatry was consulted six days after transplant for hyperactivity, disruptive behaviors, physical agitation, impaired cognition, disorientation, disorganized speech, and occasional hallucinations; these symptoms were refractory to multiple trials of psychiatric medications. After extensive medical and neurological work-up, and several instances of critically elevated tacrolimus levels, the patient was transitioned to cyclosporine, with gradual improvement, and eventual return to cognitive baseline. In exploring the possible causes of this complicated psychiatric presentation, we highlight the correlation between tacrolimus use and psychiatric symptoms, even when levels are in the therapeutic range, and emphasize the need to consider switching to an alternate agent. To our knowledge, this is the first case of tacrolimus-induced psychotic symptoms in the setting of a second organ transplant, years after initiation of tacrolimus for an initial transplant. Considering this, clinicians should remain vigilant in monitoring patients with chronic tacrolimus use, while awaiting more research into the neurotoxic implications of its long-term use.
{"title":"Delayed onset tacrolimus-induced neuropsychiatric symptoms in a pancreas-after-kidney transplant recipient","authors":"Sara Briker , Aria Vitale , Sara Wierbowski , Jonathan Galla , Kelly Hamilton , Steven Potter , Jennifer F. Schreiber","doi":"10.1016/j.psycr.2025.100295","DOIUrl":"10.1016/j.psycr.2025.100295","url":null,"abstract":"<div><div>The introduction of tacrolimus as an anti-rejection medication has markedly improved the outcomes of patients receiving organ transplants. While the use of tacrolimus has been instrumental in preventing organ rejection, especially in the case of pancreas and multi-organ transplants, the neuropsychiatric side effects are less commonly reported. Here, we present the complicated psychiatric and behavioral presentation of a 38-year-old woman with a psychiatric history of treatment-resistant depression, anxiety, and an unspecified eating disorder, who had been maintained uneventfully on tacrolimus after receiving a living-donor kidney transplant two years earlier. The patient then underwent an isolated pancreas transplant. Psychiatry was consulted six days after transplant for hyperactivity, disruptive behaviors, physical agitation, impaired cognition, disorientation, disorganized speech, and occasional hallucinations; these symptoms were refractory to multiple trials of psychiatric medications. After extensive medical and neurological work-up, and several instances of critically elevated tacrolimus levels, the patient was transitioned to cyclosporine, with gradual improvement, and eventual return to cognitive baseline. In exploring the possible causes of this complicated psychiatric presentation, we highlight the correlation between tacrolimus use and psychiatric symptoms, even when levels are in the therapeutic range, and emphasize the need to consider switching to an alternate agent. To our knowledge, this is the first case of tacrolimus-induced psychotic symptoms in the setting of a second organ transplant, years after initiation of tacrolimus for an initial transplant. Considering this, clinicians should remain vigilant in monitoring patients with chronic tacrolimus use, while awaiting more research into the neurotoxic implications of its long-term use.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100295"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1016/j.psycr.2025.100294
Felipe Londoño Gómez, Paola Hernández Rúa, Kelly Duica, Camilo Andrés Agudelo V
Delusional misidentification syndromes are a group of rare psychiatric phenomena involving disturbances in the recognition of oneself or others. Among them, delusional hermaphroditism and delusional pregnancy are exceptionally uncommon. We present the case of a 58-year-old male with bipolar disorder in a manic episode, who has a persistent belief of possessing both male and female genitalia and experiencing multiple pregnancies and miscarriages. The patient's delusional symptoms proved refractory to antipsychotic treatment, necessitating electroconvulsive therapy (ECT), which led to complete symptom resolution. This case underscores the clinical relevance of rare delusional presentations in bipolar mania and highlights the therapeutic role of ECT in treatment-resistant cases.
{"title":"Delusions of hermaphroditism and pregnancy in bipolar mania","authors":"Felipe Londoño Gómez, Paola Hernández Rúa, Kelly Duica, Camilo Andrés Agudelo V","doi":"10.1016/j.psycr.2025.100294","DOIUrl":"10.1016/j.psycr.2025.100294","url":null,"abstract":"<div><div>Delusional misidentification syndromes are a group of rare psychiatric phenomena involving disturbances in the recognition of oneself or others. Among them, delusional hermaphroditism and delusional pregnancy are exceptionally uncommon. We present the case of a 58-year-old male with bipolar disorder in a manic episode, who has a persistent belief of possessing both male and female genitalia and experiencing multiple pregnancies and miscarriages. The patient's delusional symptoms proved refractory to antipsychotic treatment, necessitating electroconvulsive therapy (ECT), which led to complete symptom resolution. This case underscores the clinical relevance of rare delusional presentations in bipolar mania and highlights the therapeutic role of ECT in treatment-resistant cases.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100294"},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145323276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号